In addition, using this new technology, we prepared novel RNAi agents directed against TGF-β1 and their inhibitory activity was compared to canonical siRNA using in vitro assays and animal models of ALI and pulmonary fibrosis. The gene discussed is TGFB1; the disease is acute respiratory distress syndrome.